ETF Holdings Breakdown of ANAB

News associated with ANAB

Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

Barclays PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,567 shares of the biotechnology company’s stock after acquiring an additional 39,267 shares during the […] - 2025-05-05 08:26:54

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 85.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,184 shares of the biotechnology company’s stock after selling 272,059 shares during the quarter. Federated […] - 2025-04-17 08:18:48

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after purchasing an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of AnaptysBio worth $24,411,000 as […] - 2025-04-16 07:22:49

Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO)

AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Risk & Volatility AnaptysBio has a beta of […] - 2025-03-25 05:56:46

Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.11

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-25 05:52:42

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 at JPMorgan Chase & Co.

AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $36.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 156.10% from the […] - 2025-03-07 06:10:52

AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 31.34% from the company’s previous close. Several […] - 2025-03-06 08:31:49

Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-02-28 06:26:55

Jennison Associates LLC Boosts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,131 shares of the biotechnology company’s stock after acquiring an additional 4,242 shares during the […] - 2025-02-07 09:55:30

Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush […] - 2025-02-06 06:36:55

Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB)

Wolfe Research assumed coverage on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock. Several other research firms also recently commented on ANAB. Guggenheim cut their target price on […] - 2025-02-05 09:10:52

ANAB institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	16,537	USD 323,794 -0.5%
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	5,594	USD 109,531 -0.5%
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	21,872	USD 428,254 -0.5%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	14,728	USD 288,374
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	14,728	USD 288,374 -0.5%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	106	USD 2,075 -0.5%
Total =		73,565	USD 1,440,402

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer